Daily Respiratory Research Analysis
Analyzed 212 papers and selected 3 impactful papers.
Summary
Analyzed 212 papers and selected 3 impactful articles.
Selected Articles
1. Single-Cell Reveal GALNT7-Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non-Small Cell Lung Cancer.
This multi-omics study identifies GALNT7 upregulation in ICB non-responding NSCLC and shows that GALNT7 suppresses ferroptosis programs. Genetic silencing of GALNT7 triggers ferroptotic death, downregulates SLC7A11/GPX4, upregulates ACSL4, reduces tumor growth in vivo, and enhances CD8 responses.
Impact: Revealing a glycosyltransferase-driven ferroptosis brake as a resistance mechanism provides a concrete, targetable axis to potentiate ICB efficacy in lung cancer.
Clinical Implications: While preclinical, the data support therapeutic strategies that downregulate GALNT7 or co-opt ferroptosis (e.g., GPX4/SLC7A11 modulation) to overcome ICB resistance in NSCLC.
Key Findings
- GALNT7 is selectively upregulated in ICB non-responders and enriched in malignant epithelial cells.
- GALNT7 suppresses ferroptosis; its silencing induces ferroptotic death with lipid peroxidation and mitochondrial injury.
- GALNT7 loss reduces SLC7A11/GPX4 and increases ACSL4; in vivo knockdown reduces tumor growth and enhances CD8 responses.
Methodological Strengths
- Integrative single-cell, bulk, and spatial transcriptomics with in vitro and in vivo functional validation
- Mechanistic linkage between GALNT7 and ferroptosis pathway components (SLC7A11, GPX4, ACSL4)
Limitations
- Preclinical study; no prospective clinical validation of GALNT7-targeted strategies
- The abstract truncates some in vivo immune findings; full dataset details not available here
Future Directions: Design early-phase trials combining ICB with ferroptosis-augmenting agents or GALNT7 inhibitors; develop biomarkers to stratify patients by GALNT7/ferroptosis activity.
Immunotherapy has transformed the treatment of non-small cell lung cancer (NSCLC), yet most patients fail to respond due to poorly understood resistance mechanisms. Here, integrative multi-omics analysis combining single-cell RNA-sequencing, bulk RNA-seq, and spatial transcriptomics is performed on tumors from NSCLC patients receiving immune checkpoint blockade (ICB). Transcriptomic profiling revealed that GALNT7, a glycosyltransferase, is selectively upregulated in non-responders (NR) and enriched in malignant epithelial cells. Functional and pathway analyses linked GALNT7 expression to suppression of ferroptosis-related signaling, whereas ICB responders (R) exhibited higher ferroptosis activity. Silencing GALNT7 in NSCLC cells impaired proliferation, induced apoptosis, and triggered ferroptotic cell death, characterized by lipid peroxidation and mitochondrial damage. Mechanistically, GALNT7 loss decreased SLC7A11 and GPX4, while upregulating the ferroptosis activator ACSL4. In vivo, GALNT7 knockdown reduced tumor growth, enhanced CD8
2. Respiratory syncytial viral load drives ciliated cell dedifferentiation and suppresses antiviral immunity.
In human airway epithelium, RSV preferentially infects ciliated cells and, in a viral load–dependent manner, suppresses ciliogenesis, antigen presentation, and innate sensing programs. Only a minority of infected cells produce IFNs, whereas bystanders mount ISG responses; IRF1 remains intact and its ectopic expression reduces RSV replication.
Impact: Defines a load-dependent epithelial reprogramming mechanism of RSV immune evasion and nominates IRF1 as a druggable antiviral axis.
Clinical Implications: Supports strategies that enhance IRF1 activity or protect ciliated cell programs to mitigate severe RSV disease; informs biomarker development based on epithelial ISG patterns.
Key Findings
- RSV primarily infects ciliated cells and causes viral load–dependent shutdown of ciliogenesis, antigen presentation, and innate sensing pathways.
- Only a subset of infected cells produce type I/III IFNs, whereas bystander cells show strong ISG signatures.
- IRF1 expression is not suppressed by RSV; ectopic IRF1 reduces viral replication in vitro.
Methodological Strengths
- Use of primary human airway epithelial cultures with time-resolved single-cell transcriptomics and imaging
- Direct perturbational validation of IRF1’s antiviral effect
Limitations
- In vitro airway models may not fully capture in vivo immune–epithelial crosstalk
- Therapeutic modulation of IRF1 requires in vivo validation for efficacy and safety
Future Directions: Test IRF1-augmenting interventions in in vivo RSV models; evaluate ciliated cell integrity and ISG signatures as biomarkers for disease severity and treatment response.
Respiratory syncytial virus (RSV) causes severe lower respiratory disease, yet how it reshapes airway epithelial cells and evades innate immunity remains incompletely understood. We infected adult primary human airway epithelial cultures with RSV and analyzed infected and bystander cells over time using single-cell RNA sequencing and imaging. RSV mainly infected ciliated cells, triggering a virus load-dependent shutdown of genes involved in ciliogenesis, antigen presentation, and innate sensing, including key interferon (IFN) and pattern recognition pathways. Only a subset of infected cells produced type I and III IFNs, while bystander cells exhibited strong IFN-stimulated gene (ISG) signatures. Neither IFN treatment nor ISG induction eliminated infection, but IRF1, an antiviral transcription factor not suppressed by RSV, remained robustly expressed. Ectopic IRF1 expression in vitro reduced viral replication. These findings reveal how RSV evades antiviral defenses and highlight IRF1 as a potential target for therapeutic intervention.
3. Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center Study.
SCENT, a CT-based deep learning model, accurately predicted PD-L1 ≥50% and stratified survival in metastatic NSCLC across multiple cohorts, outperforming clinical and radiomics baselines. It complemented tissue IHC for prognostication and showed preliminary longitudinal utility, though prospective validation is needed.
Impact: This work advances a generalizable, noninvasive biomarker to guide ICI therapy selection and complements PD-L1 IHC, potentially reducing reliance on invasive biopsies and sampling bias.
Clinical Implications: SCENT could triage patients for ICI therapy when tissue is limited, prioritize biopsy sites, and combine with IHC to refine prognostication. Prospective trials should evaluate decision impact and integration into clinical workflows.
Key Findings
- SCENT predicted PD-L1 ≥50% with AUC 0.84 (MD Anderson), and validated with AUC 0.80 (Mayo) and 0.78 (LONESTAR).
- SCENT-derived PD-L1 stratified progression-free (HR 1.49) and overall survival (HR 1.40), comparable to tissue IHC.
- Combining SCENT with IHC provided complementary prognostic value; concordant low-low status predicted poorest OS (HR 1.45).
Methodological Strengths
- Large multi-center development with two independent external validations, including a phase III trial cohort.
- Direct comparison against clinical and radiomics baselines with survival association analyses.
Limitations
- Retrospective design with potential selection biases; lack of post-treatment tissue confirmation for longitudinal analyses.
- Model performance may vary across scanners/protocols; implementation requires workflow integration and prospective impact evaluation.
Future Directions: Prospective, multi-center impact studies to evaluate clinical decision changes and outcomes; harmonization across imaging protocols; exploration of dynamic PD-L1 tracking and integration with multi-omic biomarkers.
Immune checkpoint inhibitors (ICIs) benefit only a subset of patients with metastatic non-small cell lung cancer (NSCLC), but current selection relies on tissue PD-L1 immunohistochemistry (IHC), which is invasive and prone to sampling bias. We developed and validated SCENT (Scalable Ensemble Transformer), a CT-based deep learning model for noninvasive prediction of PD-L1 status and immunotherapy outcomes. In this retrospective study, 972 stage IV NSCLC patients treated with ICIs at MD Anderson were analyzed; SCENT was developed and validated in 640 patients with paired CT and PD-L1 IHC, and clinical applicability was assessed in an additional 332 CT-only patients. Generalizability was evaluated in independent cohorts from Mayo Clinic (n=72) and the phase III LONESTAR trial (n=116), where paired baseline and 3-month CT enabled longitudinal assessment. SCENT classified PD-L1 status (50% or higher vs lower) in the MD Anderson cohort with AUC 0.84 (95% CI 0.799 to 0.882), specificity 83.9%, and sensitivity 85.3%, outperforming clinical and radiomics models; external validation achieved AUC 0.80 (Mayo) and 0.78 (LONESTAR). SCENT-derived PD-L1 stratified progression-free survival (HR 1.49, p<0.001) and overall survival (HR 1.40, p=0.009), comparable to IHC, and provided complementary prognostic value when combined with IHC, with concordant low-low patients showing the poorest survival (OS HR 1.45, p=0.008). In LONESTAR, serial SCENT-inferred PD-L1 status showed a borderline association with 3-month progression without paired post-treatment tissue confirmation. SCENT is a generalizable CT-based virtual biopsy for baseline PD-L1 prediction and complementary tissue IHC stratification, with longitudinal use requiring prospective validation.